Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Have been exposed to AVONEX within approximately 1 week of conception or during the first trimester of pregnancy.~* Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively).~* Provide verbal consent to participate in the Registry.~* Verbally provide contact information for herself, her HCP, and the infant's HCP (if applicable).~NOTE: Other protocol defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregnant participants (Type: None): Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).